What Is the Real Gain After Liver Transplantation?
|
|
- Debra Kelley
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom; and Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom Received April 3, 9; accepted August 6, 9. Key Points 1. For most liver allograft recipients, both the quality and length of life are greatly improved after transplantation. However, neither the quality of life nor the length of life in the survivors returns to that seen in age-matched and sex-matched normal subjects. 2. The gain in survival after transplantation can be estimated by a comparison of the actual outcome after transplantation and the predicted survival in the absence of transplantation. 3. The reduction in graft and patient survival, in comparison with a normal age-matched and sexmatched population, is determined by several factors: short-term survival is affected by the patient s condition pre-transplant and the quality of the graft, and for longer term survival, recurrent disease accounts for most of the differences seen between different indications. Some of the causes of premature death (such as infection, de novo malignancy, and cardiovascular and cerebrovascular disease) that are increased in the liver allograft recipient may be reduced by improved management with more aggressive surveillance and treatment. 4. The aims of selection and allocation vary in different health care systems: transparency, objectivity, equity of access, justice, mortality awaiting transplantation, utility, and transplant benefit are all important but often competing demands. Understanding the associated increase in survival will allow for a rational approach to this complex area. Liver Transpl 15: S1-S5, 9. 9 AASLD. Liver transplantation has become an accepted form of therapy for patients with end-stage liver disease: indications include an anticipated survival in the absence of transplantation of less than 1 year [as suggested by an adjusted Model for End-Stage Liver Disease (MELD) score above approximately 15] and a quality of life that is unacceptable to the patient. Over the last 3 decades, overall patient and graft survival has improved, despite a lowering of the quality of the grafts, an increase in the use of extended donor criteria grafts, and a reduction in the contraindications. Although there have been many advances in surgical and anesthetic techniques and an increase in the number and classes of immunosuppressive agents available to the clinician, most of the improvements in survival are associated with a reduction in early mortality (less than 6 months), 1 and rates of late graft loss have not improved greatly. Of course, there are many possible explanations for this failure to improve long-term outcomes, and they include changes in the case mix and in the quality of the grafts used. IMPROVEMENT IN SURVIVAL ASSOCIATED WITH TRANSPLANTATION For obvious reasons, there have been no formal randomized trials comparing outcomes of transplantation with those of conservative management. However, whether liver transplantation is associated with an increase in survival can be tested by a simple comparison of the observed outcome and the outcome predicted by prognostic models. Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; FHF, fulminant hepatic failure; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SIR, standardized incidence ratio (%). Address reprint requests to James Neuberger, Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom B15 2TH. Telephone: ; FAX: ; j.m.neuberger@bham.ac.uk DOI 1.12/lt Published online in Wiley InterScience ( Liver Transplantation, Vol 15, No 11, Suppl 2 (November), 9: pp S1-S5 S1
2 S2 NEUBERGER Figure 1. Actual and predicted survival of patients transplanted for primary biliary cirrhosis in the first cohort of patients ( ) and the second cohort of patients ( ). The expected survival was calculated from a disease-specific model. Reprinted with permission from Hepatology. 2 Copyright 1, American Association for the Study of Liver Diseases. [Color figure can be viewed in the online issue, which is available at How to Measure Improvement in Survival Assessing the survival benefit of transplantation can be done by a comparison of outcomes from the time of listing (intention to treat) or from the time of transplantation. The method of choice will depend on the question to be addressed. For instance, for a patient with small liver cell cancer and hepatitis C virus related cirrhosis, the comparison of outcomes of transplantation with those of resection should use survival from listing, whereas for an assessment of the survival gain from transplantation associated with, for example, cryptogenic cirrhosis or other indications for which there is no effective treatment, the comparison of outcomes should be from the date of transplantation. The use of prognostic models to assess survival in the absence of transplantation is attractive and is probably the best option but is subject to limitations, and caution must be applied when data generated from such prognostic models are used. These models are usually derived from historical and retrospectively collected series, so extrapolation to the transplant candidate population may lead to inappropriate conclusions; furthermore, the models often do not take into account advances in diagnosis and treatment or changes in referral. Additionally, in many models, those who were transplanted are censored and not included in the modeling set. Some models are developed to assess survival from a stage of disease well before transplantation, so variables associated with death or survival occurring, for example, 1 years before the endpoint may be different or have different weights at a time nearer the endpoint. However, despite these caveats, the comparisons do validate the very clear clinical impression that transplantation does increase survival. These comparisons between actual and predicted survival do provide an estimate of the survival benefit. For example, an early analysis of survival benefit in patients undergoing transplantation for primary biliary cirrhosis showed an improvement in overall survival between 2 cohorts (Fig. 1); however, the survival benefit, as demonstrated by the difference between observed survival after transplantation and anticipated survival (as judged from a disease-specific prognostic model), decreased over time. There are many potential explanations for this observation, but it demonstrates that the less ill patients are at the time of grafting, the less the benefit will be. 2 Similar conclusions can be drawn from a recent analysis of three 5-year cohorts of patients grafted in our unit: the outcomes are improving, yet the increase in survival as a result of transplantation is decreasing (Fig. 2). The MELD model was used for the prediction of survival in the absence of transplantation, but it should be noted that the MELD model was derived from and validated in a US population and does not apply that closely to UK patients. 3 Furthermore, the MELD model was developed for the estimation of short-term survival in those undergoing intrahepatic stenting; indeed, modifications have been suggested, and over time, the weights of the variables have been adjusted. Further improvements in accuracy may be made by the inclusion of serum sodium. It is also clear that the components of the model may be affected by a variety of factors, including gender, variations in the methods used for the measurement of analytes, and compounding factors such as hemolysis. Nonetheless, the model is effective and robust, and the data are clear. Those with a worse prognosis without transplantation have a greater transplant benefit (Fig. 3); because of careful donor-recipient matching by the clinician, outcomes are little different in comparison with the outcomes of those with a better prognosis (as shown by a lower MELD), although resource utilization may be greater. Survival benefit is affected by many factors, including donor factors (as shown by the donor risk index, for example) and the status of the patient at the time of transplantation. Furthermore, the transplant benefit is affected by the indication. 4,5 It must be recognized too that the benefit will vary according to the time period over which the benefit is calculated: selecting a benefit period of 5 or years will affect the selection of the transplant candidate. LOSS OF LIFE YEARS AFTER TRANSPLANTATION Liver allograft recipients, like other recipients of solid organ grafts, are at risk from a number of conditions,
3 WHAT IS THE REAL GAIN? S3 Figure 2. Actual survival after transplantation and predicted survival in the absence of transplantation (predicted with the unadjusted MELD model) for patients transplanted in Birmingham (A) between 1994 and 1998 and (B) between 4 and 8. Abbreviation: MELD, Model for End-Stage Liver Disease. [Color figure can be viewed in the online issue, which is available at Figure 3. Actual and predicted survival (according to the unadjusted MELD score) of patients transplanted in Birmingham between 1994 and 8 with MELD scores (A) greater than 3 and (B) lower than 15. Abbreviation: MELD, Model for End-Stage Liver Disease. [Color figure can be viewed in the online issue, which is available at com.] including disease recurrence and side effects of immunosuppression: the latter may be generic (such as an increase in infections and some de novo malignancies) or class-specific or drug-specific (such as renal impairment or diabetes). It is therefore not surprising that some of these conditions will affect patient survival. There is a great variation between the rates of recurrence and the rates of graft loss from recurrence (Fig. 4); graft loss due to disease recurrence is, in our experience, greatest for hepatitis C virus infection, primary sclerosing cholangitis, and autoimmune hepatitis. 6 Indeed, variations in the impact of recurrence is the major cause of the different rates of graft survival. Liver allograft recipients have an increased risk of and increased mortality from cardiovascular and cerebrovascular disease, infection, and de novo malignancy (Fig. 5). 6,7 Interventions, such as aggressive treatment of diabetes, hyperlipidemia, and hypertension, prevention of renal impairment, and screening for selected malignancies, may reduce the increased mortality rate. Against this background, it is not surprising that liver allograft recipients have reduced survival in comparison with an age-matched population. The extent of the life years can be readily estimated by a comparison of the outcomes of transplant recipients with those of age-matched and sex-matched normal subjects. Such an analysis must be tempered by the observation that the liver transplant recipients are, apart from the liver
4 S4 NEUBERGER Figure 4. Rate of graft loss from recurrent disease. Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; FHF, fulminant hepatic failure; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis. Reprinted with permission from Transplant International. 6 Copyright 8, European Society for Organ Transplantation lifeyears lifeyears Adult liver transplant recipients Equivalent UK population Life expectancy (years) ( ) ( ) 6.5 lifeyears ( ) 1.8 lifeyears ( ) 4.2 lifeyears ( ) Age group Figure 5. Relative increase in de novo cancers after liver transplantation. Abbreviation: SIR, standardized incidence ratio (%). Reprinted with permission from Transplantation. 8 Copyright 5, Lippincott Williams & Wilkins. disease, healthy, and unlike the controls, those potential candidates with, for example, advanced cardiac or respiratory diseases will be excluded from transplantation. According to own analysis, UK adult liver transplant recipients who survive the first postoperative year will have an estimated 7.7-year reduction in life expectancy. 1 The extent of life years depends on several factors, including age, gender, and indications (Figs. 6-8). The younger recipients have the greatest number of life years ; this is possibly because the impact of immunosuppression (as discussed previously) is likely Figure 6. Predicted survival (in years) of adults who have received a liver transplant and survived 1 year and a matched UK population. Reprinted with permission from Gut. 1 Copyright 7, British Society of Gastroenterology. [Color figure can be viewed in the online issue, which is available at www. interscience.wiley.com.] to exist regardless of age. These data do provide an indication of life expectancy after transplantation and should be helpful to recipients and their families in understanding what to expect for the future and in planning for their future. Of course, caution must be taken in extrapolating these predictions, which are based on historical data, to an individual. It should be noted that these studies address survival and take no account of quality of life. Thus, a patient grafted for intractable pruritus or severe encephalopathy in the context of good graft function may have a dramatic improvement in the quality of life and a sig-
5 WHAT IS THE REAL GAIN? S5 Life expectancy (years) years years years years years Similarly, for those with liver cell cancer, changes in selection and preoperative and postoperative management are likely to affect survival. When we look at gains in survival, it is not clear whether outcomes after transplantation have to be compared with outcomes after other treatment modalities such as resection, chemotherapy, and loco-regional therapies or after no treatment. In clinical practice, the different therapeutic options are usually complementary rather than competitive. There have been very few adequately powered prospective studies comparing transplantation with other therapies: the studies have been mainly retrospective comparisons of 2 treatment modalities or an evaluation of a settled protocol, so it has not been possible to do a full comparison. PBC PSC Crypto AIH HBV Alcohol HCV Cancer Figure 7. Life expectancy for males who have survived 1 year according to age and indication. Reprinted with permission from Gut. 1 Copyright 7, British Society of Gastroenterology. [Color figure can be viewed in the online issue, which is available at Life-years PBC PSC Crypto AIH HBV Alcohol HCV Cancer Males nificant gain in quality-adjusted life years, although the gain in survival alone may be minimal. Issues surrounding quality of life are discussed elsewhere. Hepatitis B virus It is difficult to predict the survival benefit of those with hepatitis B virus infection, as the introduction of safe and effective agents to prevent infection of the graft means that historical data cannot be used to predict future life expectancy. Liver Cell Cancer Females years years years years years Figure 8. Life years gained or according to age and indication in males who have survived 1 year post-transplant. Reprinted with permission from Gut. 1 Copyright 7, British Society of Gastroenterology. [Color figure can be viewed in the online issue, which is available at com.] CONCLUSION An understanding of the gain in survival and quality of life after transplantation is important for providers of health care, for patients and their families, and for health care professionals. Furthermore, consideration of outcomes is a key component of any allocation system. A clear understanding of transplant benefit and those donor and pretransplant and posttransplant recipient factors that affect outcome will allow for a rational debate and evidence-based systems of selection and allocation. ACKNOWLEDGMENT The help from Bridget Gunson in generating some of the data is gratefully acknowledged. REFERENCES 1. Barber K, Blackwell J, Collett D, Neuberger J, for the UK Liver Transplant Advisory Group. Life expectancy for adult liver allograft recipients in the UK. Gut 7;56: Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 4 patients in a single center. Hepatology 1;33: Freeman RB, Jamieson N, Schaubel DE, Porte RJ, Villiamil FG. Who should get a liver graft? J Hepatol 9; 5: Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, Merion RM. Survival benefit-based deceased-donor allocation. Am J Transplant 9;9: Lucey M, Schaubel DE, Guidinger MK, Tome S, Merion R. Effects of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 9;5: Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 8;21: Mells G, Neuberger J. Long term care of the liver allograft recipient. Semin Liver Dis 9;29: Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger J. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 5;8:
Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
LIVER TRANSPLANTATION 16:130-137, 2010 ORIGINAL ARTICLE Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationType of intervention Other: transplantation. Economic study type Cost-utility analysis.
Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups Longworth L, Young T, Buxton M J, Ratcliffe J, Neuberger J, Burroughs A, Bryan S Record Status
More informationSerum Sodium and Survival Benefit of Liver Transplantation
LIVER TRANSPLANTATION 21:308 313, 2015 ORIGINAL ARTICLE Serum Sodium and Survival Benefit of Liver Transplantation Pratima Sharma, 1 Douglas E. Schaubel, 2 Nathan P. Goodrich, 4 and Robert M. Merion 3,4
More informationThe Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease
LIVER TRANSPLANTATION 14:235-239, 2008 ORIGINAL ARTICLE The Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease Elizabeth J. Carey, Manjushree Gautam, 3 Timothy
More informationLiver Transplantation in the United Kingdom
TRANSPLANT INTERNATIONAL Liver Transplantation in the United Kingdom James Neuberger Organ Donation and Transplantation, National Health Service Blood and Transplant, Bristol, UK; and Queen Elizabeth Hospital,
More informationGeographic Differences in Event Rates by Model for End-Stage Liver Disease Score
American Journal of Transplantation 2006; 6: 2470 2475 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationLiver Transplant: Alcoholic liver disease as first indication
Monotematica AISF The future of liver disease: beyond HCV there is a role for hepatologist? Milano, 13-15 Ottobre 2016 Liver Transplant: Alcoholic liver disease as first indication Giacomo Germani Multivisceral
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationLong-term Outcomes After Third Liver Transplant
ArtıcLe Long-term Outcomes After Third Liver Transplant C. Burcin Taner, 1 Deniz Balci, 1 Darrin L. Willingham, 1 Andrew P. Keaveny, 1 Barry G. Rosser, 1 Juan M. Canabal, 1 Timothy S. J. Shine, 2 Denise
More informationLiver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
More informationFor the past two decades, the number of patients
When Shouldn t We Retransplant? Michael A. Zimmerman and R. Mark Ghobrial Key Points 1. In the setting of early graft failure after primary transplantation, orthotopic liver retransplantation (re-olt)
More informationLate Protocol Liver Biopsies in the Liver Allograft: A Neglected Investigation?
LIVER TRANSPLANTATION 15:931-938, 2009 ORIGINAL ARTICLE Late Protocol Liver Biopsies in the Liver Allograft: A Neglected Investigation? George Mells, 1 Caroline Mann, 1 Stefan Hubscher, 2 and James Neuberger
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationRemoving Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs
LIVER TRANSPLANTATION 14:303-307, 2008 ORIGINAL ARTICLE Removing Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs Kevin P. Charpentier 1 and Arun Mavanur 2 1 Rhode
More informationOverall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationCirrhosis secondary to chronic hepatitis C viral
Effect of Alcoholic Liver Disease and Hepatitis C Infection on Waiting List and Posttransplant Mortality and Transplant Survival Benefit Michael R. Lucey, 1 Douglas E. Schaubel, 2,3 Mary K. Guidinger,
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationFrequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationChronic liver failure Assessment for liver transplantation
Chronic liver failure Assessment for liver transplantation Liver Transplantation Dealing with the organ shortage Timing of listing must reflect length on waiting list Ethical issues Justice, equity, utility
More informationQuantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
More informationSupplementary Digital Content
Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy
More informationDetecting Lifetime Alcohol Problems in Individuals Referred for Liver Transplantation for Nonalcoholic Liver Failure
LIVER TRANSPLANTATION 14:1609-1613, 2008 ORIGINAL ARTICLE Detecting Lifetime Alcohol Problems in Individuals Referred for Liver Transplantation for Nonalcoholic Liver Failure Ed Day, 1 David Best, 1 Ruth
More informationLiver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract
Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract
More informationPAPER. Liver Transplant for Hepatitis C Virus. Effect of Using Older Donor Grafts on Short- and Medium-Term Survival
PAPER Liver Transplant for Hepatitis C Virus Effect of Using Older Donor Grafts on Short- and Medium-Term Survival M. B. Majella Doyle, MD; Christopher D. Anderson, MD; Neeta Vachharajani, MD; Jeffrey
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationFollowing the introduction of adult-to-adult living
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION Liver Transplant Recipient Survival Benefit with Living Donation in the Model for Endstage Liver Disease Allocation Era Carl L. Berg, 1 Robert M. Merion, 2 Tempie
More informationLiver Transplantation By: Kay R. Brown, CLCP
Liver Transplantation By: Kay R. Brown, CLCP Dr. Jeffrey Crippin, Director of Hepatology at the Baylor Institute of Transplantation in Dallas, Texas outlined during the Transplantation '97 seminar the
More informationNHS BLOOD AND TRANSPLANT LIVER ADVISORY GROUP. Protocols and Guidelines for Adults Undergoing Deceased Donor Liver Transplantation in the UK
NHS BLOOD AND TRANSPLANT LIVER ADVISORY GROUP Protocols and Guidelines for Adults Undergoing Deceased Donor Liver Transplantation in the UK PROTOCOLS AND GUIDELINES CONTENTS Summary 1 1 Introduction 2
More information. Time to transplant listing is dependent on. . In 2003, 9.1% of all prevalent transplant. . Patients with diabetes mellitus are less
Chapter 5: Joint Analyses with UK Transplant in England and Wales; Access to the Renal Transplant Waiting List, Time to Listing, Diabetic Access to Transplantation and the Influence of Social Deprivation
More informationPATIENT SELECTION FOR DECEASED DONOR KIDNEY ONLY TRANSPLANTATION
PATIENT SELECTION FOR DECEASED DONOR KIDNEY ONLY TRANSPLANTATION This policy has been created by the Kidney Advisory Group on behalf of NHSBT. The policy has been considered and approved by the Organ Donation
More informationThe Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
LIVER TRANSPLANTATION 12:652-658, 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro,
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationShould Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores < 14 Be Avoided? A Decision Analysis Approach
LIVER TRANSPLANTATION 15:242-254, 2009 ORIGINAL ARTICLE Should Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores < 14 Be Avoided? A Decision Analysis Approach James D. Perkins,
More informationRecurrence of hepatitis C virus (HCV) after orthotopic. Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame?
RAPID COMMUNICATION Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame? Kymberly D.S. Watt, Elizabeth R. Lyden, and Timothy M. McCashland Data from 1990 to 1996 suggest that the prevalence
More informationImpact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index
LIVER TRANSPLANTATION 14:321-326, 2008 ORIGINAL ARTICLE Impact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index Amy A. Dan, 1,2 Jillian B. Kallman, 1,2
More informationResearch Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationEffect of Body Mass Index on the Survival Benefit of Liver Transplantation
LIVER TRANSPLANTATION 13:1678-1683, 2007 ORIGINAL ARTICLE Effect of Body Mass Index on the Survival Benefit of Liver Transplantation Shawn J. Pelletier, 1 Douglas E. Schaubel, 2,3 Guanghui Wei, 2 Michael
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationDisparities in Liver Transplant Allocation: An Update on MELD Allocation System
Disparities in Liver Transplant Allocation: An Update on MELD Allocation System Naudia L. Jonassaint, MD MHS Assistant Professor of Medicine and Surgery University of Pittsburgh School of Medicine Historical
More informationCombined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database
LIVER TRANSPLANTATION 21:1486 1493, 2015 ORIGINAL ARTICLE Combined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database Joris J. Blok, 1 Hein
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More information4/26/2017. Liver Transplant and Palliative Care: Teaming up to improve care
Liver Transplant and Palliative Care: Teaming up to improve care Jody C. Olson, M.D., FACP Assistant Professor of Medicine and Surgery Hepatology and Critical Care Medicine All patients with end-stage
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationRAPID COMMUNICATION Preexisting malignancy is considered a relative contrain- dication to orthotopic liver transplantation (OLT) be-
RAPID COMMUNICATION Successful Outcome of Orthotopic Liver Transplantation in s With Preexisting Malignant States Sanjiv Saigal, Suzanne Norris, Parthi Srinivasan, Paolo Muiesan, Mohamed Rela, Nigel Heaton,
More informationIn the United States, the Model for End-Stage Liver. Re-weighting the Model for End-Stage Liver Disease Score Components
GASTROENTEROLOGY 2008;135:1575 1581 Re-weighting the Model for End-Stage Liver Disease Score Components PRATIMA SHARMA,* DOUGLAS E. SCHAUBEL,, CAMELIA S. SIMA,, ROBERT M. MERION,, and ANNA S. F. LOK* *Division
More informationOntario s Adult Referral and Listing Criteria for Liver Transplantation
Ontario s Adult Referral and Listing Criteria for Liver Transplantation Version 3.0 Trillium Gift of Life Network Ontario s Adult Referral & Listing Criteria for Liver Transplantation PATIENT REFERRAL
More informationDe novo malignancy occurs more commonly after. Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation
GASTROENTEROLOGY 2009;137:2010 2017 Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation KYMBERLY D. S. WATT,* RACHEL A. PEDERSEN, WALTER K. KREMERS, JULIE K. HEIMBACH,
More informationSurvival Benefit-Based Deceased-Donor Liver Allocation
American Journal of Transplantation 2009; 9 (Part 2): 970 981 Wiley Periodicals Inc. No claim to original US government works Journal compilation C 2009 The American Society of Transplantation and the
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationSurvival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor
LIVER TRANSPLANTATION 15:1343-1350, 2009 ORIGINAL ARTICLE Survival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor Lei Yu, 1-3 Thomas Koepsell,
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationORIGINAL ARTICLE Gastroenterology & Hepatology INTRODUCTION
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.8.1207 J Korean Med Sci 2013; 28: 1207-1212 The Model for End-Stage Liver Disease Score-Based System Predicts Short
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationEffects of Allocating Livers for Transplantation Based on Model for End-stage Liver Disease-Sodium Scores on Patient Outcomes
Accepted Manuscript Effects of Allocating Livers for Transplantation Based on Model for End-stage Liver Disease-Sodium Scores on Patient Outcomes Shunji Nagai, MD, PhD, Lucy C Chau, HBSc, MMI, Randolph
More informationReview Article Experience Since MELD Implementation: How Does the New System Deliver?
International Hepatology Volume 2012, Article ID 264015, 5 pages doi:10.1155/2012/264015 Review Article Experience Since MELD Implementation: How Does the New System Deliver? Markus Quante, Christoph Benckert,
More informationClinical Study The Impact of the Introduction of MELD on the Dynamics of the Liver Transplantation Waiting List in São Paulo, Brazil
Transplantation, Article ID 219789, 4 pages http://dx.doi.org/1.1155/214/219789 Clinical Study The Impact of the Introduction of MELD on the Dynamics of the Liver Transplantation Waiting List in São Paulo,
More informationEvaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study
Original article: Evaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study Mukesh Agarwal Assistant Professor, Department of General Medicine, Teerthanker Mahaveer Medical College & Research
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationSimply stated, the major indications for liver transplantation. Indications for Liver Transplantation. Referral for Transplant Evaluation
GASTROENTEROLOGY 2008;134:1764 1776 Indications for Liver Transplantation Jacqueline G. O Leary Rita Lepe Gary L. Davis Hepatology, Department of Medicine, Baylor University Medical Center, Dallas, Texas
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationORIGINAL ARTICLE. Received April 30, 2007; accepted June
LIVER TRANSPLANTATION 13:1405-1413, 2007 ORIGINAL ARTICLE Human Leukocyte Antigen and Adult Living- Donor Liver Transplantation Outcomes: An Analysis of the Organ Procurement and Transplantation Network
More informationHong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver
Hong Kong Journal Nephrol of 2000;(2):79-83. Nephrology 2000;2(2):79-83. ORIGINAL A R T I C L E A point score system for allocating cadaveric kidneys for transplantation based on patient age, waiting time
More informationPeritransplant Pancreatitis: A Marker of High Mortality and Graft Failure in Liver Transplant Patients
ORIGINAL ARTICLE RUSSELL ET AL. Peritransplant Pancreatitis: A Marker of High Mortality and Graft Failure in Liver Transplant Patients Tara A. Russell, 1 Sarah Park, 2 Vatche G. Agopian, 3 Ali Zarrinpar,
More informationKidney Transplant Outcomes In Elderly Patients. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Kidney Transplant Outcomes In Elderly Patients Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case Discussion 70 year old Asian male, neuropsychiatrist, works full
More informationChronic liver allograft dysfunction. An unsolved problem
Chronic liver allograft dysfunction An unsolved problem % patient survival % patient survival 100 Kaplan-Meier estimates by sex and age group 100 90 90 80 80 70 70 60 60 50 50 40 40 30 20 10 Males Females
More informationContinuous Peritransplant Assessment of Consciousness using Bispectral Index Monitoring for Patients with Fulminant Hepatic Failure
Continuous Peritransplant Assessment of Consciousness using Bispectral Index Monitoring for Patients with Fulminant Hepatic Failure Purpose: Deterioration of consciousness is the most critical problem
More informationInformation for patients (and their families) waiting for liver transplantation
Information for patients (and their families) waiting for liver transplantation Waiting list? What is liver transplant? Postoperative conditions? Ver.: 5/2017 1 What is a liver transplant? Liver transplantation
More informationLiver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database
Title Liver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database Author(s) Zheng, J; Xiang, J; Zhou, J; Li, Z; Hu, Z; Lo, CM; Wang,
More informationTHE NORDIC LIVER TRANSPLANT REGISTRY ANNUAL REPORT Report prepared by Kristian Bjøro
THE NORDIC LIVER TRANSPLANT REGISTRY ANNUAL REPORT 2 Report prepared by Kristian Bjøro March 21 1 Nordic liver transplant registry - 2 As of December 31.2 the registry comprised data on 2167 patients of
More informationDynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy
Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy Liana Gheorghe 1, Speranta Iacob 1, Razvan Iacob 1, Gabriela Smira 1, Corina Pietrareanu 1, Doina
More informationCase 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
More informationDiabetes, Hypertension and Hyperlipidemia: Prevalence Over Time and Impact on Long-Term Survival After Liver Transplantation
American Journal of Transplantation 2012; 12: 2181 2187 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04077.x
More informationEvaluation Process for Liver Transplant Candidates
Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection
More informationDeath in patients waiting for liver transplantation. Liver Transplant Recipient Selection: MELD vs. Clinical Judgment
ORIGINAL ARTICLES Liver Transplant Recipient Selection: MELD vs. Clinical Judgment Michael A. Fink, 1,2 Peter W. Angus, 1 Paul J. Gow, 1 S. Roger Berry, 1,2 Bao-Zhong Wang, 1,2 Vijayaragavan Muralidharan,
More informationThe Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
More informationThe hepatopulmonary syndrome (HPS) occurs
Prospective Evaluation of Outcomes and Predictors of Mortality in Patients With Hepatopulmonary Syndrome Undergoing Liver Transplantation Miguel R. Arguedas, 1 Gary A. Abrams, 1 Michael J. Krowka, 2 and
More informationASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES
ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES James YY Fung MBChB, MD, FRACP, FHKCP, FHKAM Consultant & Hon. Assoc. Professor Liver Transplant Center Department of Surgery, Queen Mary
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationWhat s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis
What s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis A combination of improved surgical techniques, donor organ preservation, selection
More informationA study of serum ferritin as a prognostic marker in patients with decompensated liver disease
Original Research Article A study of serum ferritin as a prognostic marker in patients with decompensated liver disease P. Arul 1, S. Sangeetha 2* 1 Senior Assistant Professor, Department of General Medicine,
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationCryptogenic Cirrhosis: An Approach To The Diagnosis In The Era Of Molecular and Genomic Medicine
Cryptogenic Cirrhosis: An Approach To The Diagnosis In The Era Of Molecular and Genomic Medicine Introduction and historical perspective: Cryptogenic cirrhosis(cc) is defined as cases of cirrhosis where
More informationIndex. Note: Page numbers of article titles are in boldface type. Heart Transplantation
Heart Transplantation Index Note: Page numbers of article titles are in boldface type. Accelerated graft atherosclerosis (AGA), post heart transplantation, 73-74 Acute rejection, of heart, in adults, 70
More informationCombined Orthotopic Heart and Liver Transplantation: The Need for Exception Status Listing 1
SHORT REPORTS Combined Orthotopic Heart and Liver Transplantation: The Need for Exception Status Listing 1 Paige M. Porrett, 1 Shashank S. Desai, 2 Kathleen J. Timmins, 3 Carol R.Twomey, 4 Seema S. Sonnad,
More informationUK Liver Transplant Audit
November 2012 UK Liver Transplant Audit In patients who received a Liver Transplant between 1 st March 1994 and 31 st March 2012 ANNUAL REPORT Advisory Group for National Specialised Services Prepared
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More information